These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 62426)

  • 1. The natural modulation of the amplification phase of complement activation.
    Fearon DT; Daha MR; Weiler JM; Austen KF
    Transplant Rev; 1976; 32():12-25. PubMed ID: 62426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Control of the amplification convertase of complement by the plasma protein beta1H.
    Weiler JM; Daha MR; Austen KF; Fearon DT
    Proc Natl Acad Sci U S A; 1976 Sep; 73(9):3268-72. PubMed ID: 1067618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
    Medicus RG; Götze O; Müller-Eberhard HJ
    J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
    Fearon DT; Austen KF
    J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C3 requirements for formation of alternative pathway C5 convertase.
    Daha MR; Fearon DT; Austen KF
    J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Pangburn MK; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.
    Fearon DT; Austen KF
    Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1683-7. PubMed ID: 266208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.
    Fearon DT; Austen KF
    J Exp Med; 1975 Oct; 142(4):856-63. PubMed ID: 1185108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properdin: initiation of alternative complement pathway.
    Fearon DT; Austen KF
    Proc Natl Acad Sci U S A; 1975 Aug; 72(8):3220-4. PubMed ID: 1059108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
    Schreiber RD; Medicus RG; Gïtze O; Müller-Eberhard HJ
    J Exp Med; 1975 Sep; 142(3):760-72. PubMed ID: 1165475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A molecular concept of the properdin pathway.
    Medicus RG; Schreiber RD; Götze O; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1976 Feb; 73(2):612-6. PubMed ID: 54923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B.
    Daha MR; Fearon DT; Austen KF
    Immunology; 1976 Nov; 31(5):789-96. PubMed ID: 992711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
    Daha MR; Fearon DT; Austen KF
    J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A molecular basis of activation of the alternative pathway of human complement.
    Austen KF; Fearon DT
    Adv Exp Med Biol; 1979; 120B():3-17. PubMed ID: 390986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
    Whaley K; Schur PH; Ruddy S
    J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation of C3 cleavage in the alternative complement pathway.
    Fearon DT; Austen KF
    J Immunol; 1975 Nov; 115(5):1357-61. PubMed ID: 809512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C3 and C5-cleaving properdin enzymes formed on zymosan incubated with human serum: the decay and the regeneration of the enzymes.
    Fujita T; Takiuchi M; Matsumoto M; Nagaki K; Inai S
    Int Arch Allergy Appl Immunol; 1977; 53(4):303-9. PubMed ID: 67089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Fearon DT
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.